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Should  a highly  pathogenic  avian  inﬂuenza  virus,  such  as  the  H5N1  virus  type  currently  circulating  in
birds,  become  transmissible  among  humans,  an effective  vaccine,  rapidly  available  in vast  quantities,
would  be  the  best  tool  to  prevent  high  case-fatalities  and  the  breakdown  of  health  and  social services.
The  number  of  vaccine  doses  that  could  be produced  on  demand  has  risen  sharply  over  the  last  few
years;  however,  it is  still  alarmingly  short  of  the  13  billion  doses  that  would  be  needed  if two  doses  were
required  to protect  fully  the  world’s  population.  Most  developing  countries  would  be  last  in the queue
to  beneﬁt  from  a pandemic  vaccine.  The  World  Health  Organization,  together  with  governments,  the
pharmaceutical  industry  and  other  stakeholders,  has  been  implementing  the  global  pandemic  inﬂuenza
action  plan  to increase  vaccine  supply  since  2006.  Building  capacity  in  developing  countries  to  manu-
facture  inﬂuenza  vaccine  is an  integral  part  of  this  plan,  as  well  as  research  and  development  into  more
efﬁcacious  technologies,  e.g.  those  that  allow  signiﬁcant  dose-sparing.  To  this  end,  the  inﬂuenza  vaccine
technology  transfer  initiative  was  launched  in  2007  and,  to  date,  vaccine  manufacturers  in  11 devel-
oping  countries  have  received  grants  to  acquire  the  capacity  to  produce  inactivated  or  live  attenuated
inﬂuenza  vaccine  for their  populations.  In addition,  a centralized  ‘hub’  has  been  established  to  facilitate
training  in  the  new  technologies  for  scientists  and  regulators  in  the  countries.  This  supplement  of  Vaccine
is  devoted  to  showcasing  the  interim  results  of the  WHO  initiative  and  the  impressive  progress  made  by
the  developing  country  manufacturers.
©  2011  World  Health  Organization.  Published  by  Elsevier  Ltd.    Open access under CC BY-NC-ND license.. Introduction
The world has been on its guard against avian inﬂuenza (A)H5N1
ver since 1997, when a highly pathogenic virus crossed the species
arrier to affect humans working in close contact with infected
oultry in the Hong Kong Special Administrative Region, People’s
epublic of China. Between February 2003 and December 2010, the
orld Health Organization (WHO) received reports of 516 human
5N1 inﬂuenza cases, of whom 306 died, representing a case-atality rate of over 59%. This, and the threat of an imminent, severe
andemic led the Fifty-eighth World Health Assembly in 2005
resolution WHA58.5) to urge countries to strengthen their pan-
∗ Corresponding author at: World Health Organization, Avenue Appia 20, 1211
eneva,  Switzerland. Tel.: +41 22 791 3591; fax: +41 22 791 4909.
E-mail  address: kienym@who.int (M.P. Kieny).
264-410X     ©  2011 World Health Organization. Published by Elsevier Ltd. 
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Open access demic inﬂuenza preparedness and response. The WHO  Secretariat
was requested to seek solutions to increase global capacity to pro-
duce epidemic and pandemic inﬂuenza vaccines, and to encourage
research and development (R&D) into new and improved vaccines,
particularly those that required a lower antigen content per dose.
This recommendation was  based on awareness that containment
measures, although critical, may  delay but cannot alone prevent
the spread of a deadly inﬂuenza virus.
In November 2005, WHO  convened the ﬁrst of a series of
meetings on the development and clinical evaluation of inﬂuenza
vaccines targeting viral strains with pandemic potential [1], during
which researchers, manufacturers and regulators review safety and
efﬁcacy standards, antigen-sparing strategies, and priority research
needs. These meetings complement those organized by WHO  since
2004 on the development of inﬂuenza vaccines that induce broad
spectrum and long-lasting immune responses. It was  considered
that vaccines with these characteristics could protect against anti-
under CC BY-NC-ND license.
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enic variants within a subtype and, at least partially, against
nfection by novel viruses with the potential to cause a pandemic.
.  Global action plan to increase vaccine supply
In order to address a central concern of the World Health Assem-
ly − reducing the anticipated gap between inﬂuenza vaccine
upply and demand in a pandemic situation − WHO  organized a
andmark consultation to identify the most promising approaches
o enable the immunization of the world’s 6.7 billion population
ithin the shortest possible time. Thus, in May  2006, the global
andemic inﬂuenza action plan to increase vaccine supply (GAP)
2] was agreed upon by a broad range of stakeholders represent-
ng policy makers, national immunization programmes, regulatory
uthorities, vaccine manufacturers and the research community. To
chieve the overarching goal, three mutually reinforcing strategies
ere considered urgent and essential: the promotion of seasonal
accination programmes to increase market demand and drive
roduction capacity; the expansion of manufacturing capability,
articularly in developing countries; and enhanced inﬂuenza vac-
ine R&D.
In  2006, global production capacity for seasonal inﬂuenza vac-
ine was estimated at 350 million doses. Although annual capacity
ad reached nearly 900 million doses in 2009 [3], this still falls
larmingly short of 13.4 billion pandemic doses, should two  doses
e required to elicit immunity in the entire world population within
ix months of a pandemic alert. Moreover, in 2006, 90% of inﬂuenza
accine production was located in nine countries (largely in Europe
nd North America) that represented only 10% of the global pop-
lation. Other countries, notably those in Africa, the Middle East
nd Asia, could witness a staggering death toll and a severe strain
n their health services while waiting for producing countries and
egions to have vaccinated their own populations.
In May  2007, the Sixtieth World Health Assembly, noting the
bjectives and strategies of the GAP, requested the Secretariat in
esolution WHA60.28 to seek ways to ensure the equitable sharing
f beneﬁts of inﬂuenza vaccine R&D, including the development
f capacity for inﬂuenza vaccine production in developing coun-
ries. Indeed, domestic or regional production was considered one
f the most effective strategies for vulnerable countries and regions
o have access to an inﬂuenza vaccine in the event of a pandemic.
he general consensus to increase global access to drugs, vaccines
nd diagnostics was signiﬁcantly promoted through adoption of the
lobal strategy and plan of action on public health, innovation and
ntellectual property (GSPA-PHI) by the Sixty-ﬁrst World Health
ssembly in May  2008 (resolution WHA61.21). Two  elements high-
ighted by the GSPA-PHI were the need to build and improve
apacity in developing countries, and to facilitate the transfer of
ealth-related technologies. The GSPA-PHI thus provided further
egitimacy to the WHO  strategy of enhancing inﬂuenza vaccine
roduction through technology transfer to developing countries.
Progress  by WHO, its global partners and developing countries
owards this strategy is the focus of this special edition of Vaccine.
.  WHO  inﬂuenza vaccine technology transfer initiative
In  2007, WHO  embarked on an ambitious initiative to increase
he capacity for inﬂuenza vaccine production in developing coun-
ries. To date, more than US$ 25 million have been awarded to
1 developing country manufacturers to establish or enhance this
apacity. Grants have also enabled the establishment of a centre of
xcellence for training and transfer of inﬂuenza vaccine production
echnologies to new manufacturers. In addition, WHO  has negoti-
ted a non-exclusive licence for a live attenuated inﬂuenza vaccine
LAIV) technology. A summary of the rationale behind the choice of29S (2011) A2– A7 A3
the technologies and the selection process for the awards under the
aegis of the WHO  inﬂuenza vaccine technology transfer initiative
is provided in this Section.
3.1.  Selection of technologies
In  order to assist developing country vaccine manufacturers
to identify technologies most suited to their needs, WHO  com-
missioned in 2006 a review of the technologies used to produce
the currently registered inﬂuenza vaccines [4]. The review con-
sidered whole-virion, split and subunit inactivated, as well as live
attenuated vaccines, produced either in eggs or cell culture. It also
considered the capital investment required to establish a manu-
facturing facility, the time needed for product approval, and the
relative cost of vaccine produced by each method. The review
concluded that the egg-based inactivated inﬂuenza vaccine (IIV)
production process was  potentially the easiest to establish as it is
used to produce more than 90% of vaccines available on the mar-
ket and presents few unknowns in the path to regulatory approval.
In contrast, tissue-culture based production of IIV requires much
greater ﬁnancial investment and, at the time of the review, faced
numerous regulatory questions.
For pandemic surge capacity, egg-based LAIV requires smaller
capital investment than IIV and offers signiﬁcantly higher yield,
faster quality control and release and, importantly, needle-free
administration. This made LAIV an attractive option, particularly
for developing countries with very large populations and limited
numbers of health-care workers able to administer injectable IIV
in a short period of time. However, while the LAIV manufacturing
process is simple and potentially easier to transfer to developing
countries than IIV, the production and distribution of LAIV requires
a licence agreement with one of the two technology owners (see
Section 3.3 below).
The  review did not evaluate in detail upstream vaccine tech-
nologies such as recombinant antigens, viral vector- or DNA-based
vaccines. Although promising, none of these technologies were
licensed at that time, and it was therefore premature for WHO
to recommend them to developing countries. The review did,
however, point out that the addition of adjuvants, particularly oil-
in-water emulsions, to IIV permitted signiﬁcant dose reduction and
could therefore be very useful for surge production in the event of
a pandemic.
3.2. Selection of manufacturers
Following  a ﬁrst public call for proposals via the WHO  web  site in
2007, six developing country vaccine manufacturers were awarded
grants (out of nine who applied) to establish or expand inﬂuenza
vaccine manufacturing capacity, and a further ﬁve were selected
subsequent to a second call in 2009. The 11 vaccine manufacturers
(Table 1) have received grants of between US$ 0.5−4.27 million.
All proposals were evaluated against mandatory criteria, techni-
cal merit, public health value and potential domestic and regional
impact by an independent external Technical Advisory Group. In
addition, each manufacturer was required to demonstrate govern-
ment support for its proposal − a critical element to ensuring that
manufacturing plans are in line with immunization plans.
One  mandatory criterion was that a manufacturer was produc-
ing at least one human vaccine approved by the national regulatory
agency. Given the complexity of inﬂuenza vaccine production, this
helped ensure the transfer of technology to experienced manu-
facturers, and contributed to the success of the project. However,
the criterion eliminated emerging manufacturers that were keen
to establish local inﬂuenza vaccine production but had not (yet)
registered a vaccine for human use. In order to address the urgent
need for regions such as sub-Saharan Africa to be able to produce
A4 M.  Friede et al. / Vaccine 29S (2011) A2– A7
Table  1
Developing country vaccine manufacturers selected by WHO  in 2007 and 2009.
Country Manufacturer Public or private 2007 grantee (1st round) 2009 grantee (2nd round)
Brazil Instituto Butantan Public X
Egypt Vacsera Public X
India Serum Institute of India Private X
Indonesia Bio Farma Public X
Iran Razi Institute Public X
Mexico  Birmex Public X
Republic of Korea Green Cross Corporation Private X
Romania  Cantacuzino Institute Public X
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Thailand Government Pharmaceutical Organization 
Viet Nam Institute of Vaccines and Medical Biologicals 
andemic inﬂuenza vaccine, future calls may  see modiﬁed criteria
o take this into account.
.3.  Intellectual property and know-how considerations
To complement its review of production technologies, WHO
ndertook an analysis of intellectual property (IP) issues related
o each manufacturing process to identify potential IP barriers and
reas where new manufacturers would have to seek licences [5].
he report noted that it was not patents, but access to techni-
al know-how and regulatory dossiers that potentially constituted
igniﬁcant barriers, even for conventional egg-derived inﬂuenza
accines. Thus, partnerships with technology holders were sought
o ensure the successful and rapid establishment of production
apacity.
Similarly, there are no signiﬁcant patent barriers to produce
ive attenuated inﬂuenza vaccines, which have been widely used
n Russia and the former Union of Soviet Socialist Republics for the
ast thirty years. Nonetheless, access to strains with a well docu-
ented safety and efﬁcacy proﬁle, and to corresponding regulatory
ocumentation, would avoid the lengthy and expensive process of
eriving a new LAIV through de novo attenuation of pathogenic
irus strains. To facilitate access to such attenuated strains, WHO
cquired from Nobilon (now Merck) a licence on the technology
eveloped by the Institute of Experimental Medicine in St Peters-
urg, Russia. This royalty-free licence to develop, manufacture and
ell to the public sector both seasonal and pandemic egg-derived
AIV allowed WHO  to provide sub-licences to manufacturers in
eveloping countries (see article by Rudenko et al. [8]).The  report also noted that no IP barriers existed in developing
ountries for an oil-in-water emulsion that permits considerable
ose-reduction with IIV, since patents had not been ﬁled in these
reas of the world. This opened the possibility for developing coun-
able 2
omparison of models for technology transfer.
Type Schematic diagram Adv
Bilateral Donor Recipient Idea
situ
reci
Hub
Developers
Funding
Experts 
Donor
hub 
Recipient 1 
Recipient 2 
Recipient 3
Idea
reci
techX
 X
 X
try  vaccine manufacturers to produce and use adjuvants to expand
IIV capacity in the event of a pandemic. Again, know-how was
identiﬁed as a major hurdle.
4. Technology transfer
Effective  technology transfer is arguably the most effective route
for developing countries to secure sustainable access to quality
inﬂuenza vaccine production technology. As pointed out above,
technology transfer from an entity that has a registered product is
the most effective, as this reduces risk to the recipient and facil-
itates rapid approval of the locally produced product. However,
while most major vaccine manufacturers have undertaken tech-
nology transfer for early childhood vaccines, few have been willing
to transfer their inﬂuenza vaccine technology. During the initial
phase of the WHO  inﬂuenza vaccine technology transfer initia-
tive, only three of the six grantees were successful in securing
such technology transfer partnerships. For those unable to nego-
tiate agreements, the next best approach was  to hire the services
of the few independent consultants with experience of large-scale
inﬂuenza vaccine production, to assist the new manufacturers in
setting up the production processes. However, these consultants
rapidly found themselves thinly spread, facing different strategies
for vaccine production and varying levels of capacity to absorb the
technologies. WHO  therefore decided to facilitate the creation of an
inﬂuenza vaccine technology ‘hub’ – a relatively novel concept for
vaccines. Where previous technology transfer had been bilateral
between a technology donor and single recipient, the hub model
entails the establishment of a complete manufacturing process and
enables multiple recipients to receive ‘turnkey’ technology trans-
fer. A schematic comparison of the classic bilateral model and the
hub model for technology transfer is provided in Table 2.
antages Drawbacks
l for win-win
ations where donor and
pient beneﬁt.
Not  readily feasible in cases where there is
limited ﬁnancial beneﬁt for donor.
l when multiple
pients  need the same
nology.
Not  readily feasible where multiple intellectual
property barriers exist or where know-how is
not  easily available.
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A number of conditions needed to be met  for the creation of a
uccessful inﬂuenza vaccine technology transfer hub [6]. The ﬁrst
as that the technology had to be free of intellectual property bar-
iers, both at the hub site and in recipient countries. Secondly, the
ub must have manufacturing and quality control experience and
nfrastructure in line with WHO  requirements. In addition, there
hould be no competing interest of the hub facility in the com-
ercial markets of the recipients. Lastly, ﬁnancial support must
e available to see the hub through the technology development
hase, with the premise that sustainability would be ensured at a
ater stage through ﬁnancial contributions from existing and new
echnology recipients.
Several  entities, including private contract research organiza-
ions, public vaccine development centres, and public or private
accine manufacturers, were envisaged as potential candidates
o serve the role of a hub. An open call for proposals published
n the WHO  web site resulted in the selection in 2008 of the
etherlands Vaccine Institute (NVI) as the technology hub for
nﬂuenza vaccines. NVI was a Dutch governmental vaccine man-
facturer – although not in the area of inﬂuenza – with  a successful
ecord in transferring technology (see article by Hendriks et al.
9]).
Likewise, WHO  facilitated the establishment in 2010 of a vac-
ine formulation centre of excellence at the University of Lausanne,
witzerland where the procedures for producing non-proprietary
il-in-water emulsions are being established for transfer to devel-
ping countries (see article by Collin and Dubois [10]). Establishing
he centre in Switzerland was partly inﬂuenced by the fact that
 relevant patent on submicron oil-in-water emulsions had been
evoked in Europe. While the production of oil-in-water emulsions
s not technically difﬁcult and is well described in specialized lit-
rature, numerous parameters make it more effective to establish
 centralized hub than to assist separate manufacturers to acquire
he same technology. These range from procurement of raw mate-
ials for the emulsion, selection of the appropriate manufacturing
quipment, and procedures for characterization and release of the
djuvant.
A technology transfer initiative using a concept similar to the
djuvant hub model is the ‘Enabling Platform’ [7] used by PATH to
acilitate the transfer of rotavirus vaccine technology. In this type of
pstream technology transfer, the production of reagents, quality
ontrol testing and formulation development (enabling technolo-
ies and tools) take place at different sites and serve multiple
ecipients.
Fig. 1. Annual inﬂuenza vaccine requirements, current maximum productio29S (2011) A2– A7 A5
5. Interim results of the initiative
A key measurable outcome of the initiative is the increased
capacity of the new manufacturers to contribute inﬂuenza vaccine
to their country and to the developing world in general. This is
being assessed by comparing the number of new doses of trivalent
seasonal inﬂuenza vaccine produced at the WHO  grantee man-
ufacturing sites against the 2006 baseline production. A survey
was conducted in July 2010 among all 11 developing country vac-
cine manufacturers receiving grants from WHO. The questionnaire
requested data on current seasonal inﬂuenza vaccine requirements
and target groups in the country, as well as types of vaccine to be
produced, including pandemic vaccine, production timeline, cur-
rent production, maximum capacity, and forecasted capacity by
2015. All manufacturers responded to the survey, the results of
which are summarized below.
Manufacturers in six countries (55%) reported that seasonal
inﬂuenza vaccination was currently part of their national immu-
nization programme. Two  of the remaining ﬁve countries (18%)
indicated the intent of their government to introduce inﬂuenza vac-
cination into the national immunization programme in the next ﬁve
years.
Three manufacturers (27%) reported having already produced
and distributed seasonal inﬂuenza vaccine in their countries. The
others indicated that they would commence commercial-scale vac-
cine production between 2010 and 2012. The total number of
inﬂuenza vaccine doses produced for the 2010 seasonal epidemic
was reported as 12 million, with more than 215 million doses fore-
casted to be produced annually in 2015 (Table 3). Approximately
half of these doses will be the inactivated formulation and the other
half will be LAIV. Three manufacturers produced H1N1 pandemic
vaccine in 2009 and 2010 for their country’s use, at an aggregate
total of 33 million doses as at 31 December 2010.
Finally, the survey results indicate that 9 of the 11 manufactur-
ers (82%) will be able to meet the demand for seasonal inﬂuenza
vaccine in their country by 2015 (two countries do not plan to
introduce seasonal inﬂuenza in their vaccination programme by
this date) (Fig. 1).
The  survey also estimated the investment cost in US dollars
per dose of inﬂuenza vaccine to be produced in 2015 by man-
ufacturer, based on expenditure to date, future ﬁnancial needs
and number of forecasted annual doses (Fig. 2). As predicted,
tissue-culture based technology requires signiﬁcant capital invest-
ment, whereas egg-derived LAIV requires the least investment.
n and forecasted capacity by 2015, in million doses, by manufacturer.
A6 M.  Friede et al. / Vaccine 29S (2011) A2– A7
Table  3
New  inﬂuenza vaccine production capacity (in million doses).
Company Seasonal inﬂuenza
vaccine  required
annually by national
programme
Current  production and capacity Planned
registration
(year)
Forecasted
annual
production
in 2015
Type of vaccine
Seasonal inﬂuenza
vaccine  produced
annually
H1N1 pandemic
vaccine produced
by  31 March 2010
Maximum production
capacity  (seasonal)
A 22.0 0 0 0 2011 50 Inactivated split vaccine
B 0.55 0 0 0 >2012 1.5 Inactivated whole virion
vaccine
C 12.5 10 26 20 Already
registered
10 Inactivated split vaccine
D  0 0 0 10 2010 110 Inactivated split and
LAIV
E 0.20 0 0 0 2011 4 Inactivated whole virion
F 0.40 0 0 0 >2012 0.50 Inactivated whole virion
G  20 0 0 0 2012 25 Inactivated split vaccine
H 2  2 3 2.5 Already
registered
7.5 Inactivated split vaccine
I  0.40 0 0 0 2011 2 Inactivated whole virion
J  4 0 1.5 0 2012 4 Sub unit inactivated and
LAIV
0
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Total 62.05 12 30.505 
lthough eggs can present a potential barrier to manufacture in
esource-poor settings (e.g. importation of eggs and/or mainte-
ance of hen ﬂocks), the affordability of the ﬁnal product is of
rime importance and egg-based production appears to be the
heapest.
One parameter not visible in Fig. 2 is how these costs would be
ffected by the use of adjuvants as these could multiply the num-
er of pandemic IIV doses by at least 4-fold, for minimal capital
nvestment. One of the WHO  grantee manufacturers embarked on a
rogramme for the transfer of an oil-in-water adjuvant technology
rom the Vaccine Formulation Laboratory in December 2010.
.  Discussion
Supporting selected developing countries to establish or expand
andemic inﬂuenza production capacity is not sufﬁcient to ensure
hat all developing countries have access to pandemic vaccine.
oreover, it is not possible, nor desirable to establish inﬂuenza vac-
ine production in each and every country. For this reason, WHO
rants to manufacturers are contingent upon their agreement to
ell at an affordable price 10% of their pandemic vaccine production
ig. 2. Average investment cost per dose in US$ of inﬂuenza vaccine to be produced by 1
eeds and number of forecasted annual doses. 2012 1 Inactivated whole virion
.5 215.5
to  United Nations agencies such as WHO  and UNICEF, if needed in
a pandemic event, for distribution to developing countries without
domestic production.
Other  issues require priority attention if the overall goal is to
be achieved. The concomitant training and support for regula-
tory authorities in developing countries, for example, is needed to
ensure that inﬂuenza vaccines produced there can be registered
and licensed without unnecessary delays.
Another issue of concern is the remaining geographical imbal-
ance in global inﬂuenza vaccine production capacity, and thus
access to pandemic inﬂuenza vaccine, particularly in countries in
sub-Saharan Africa. A third call for proposals to establish inﬂuenza
vaccine production capacity in developing countries will target
such regions.
In  response to growing interest by the global health commu-
nity in the development of local production to improve access to
medicines, WHO  undertook an analysis of vaccine-related tech-
nology transfer projects over the last two  decades. The analysis
identiﬁed over 100 such transfers to developing countries (princi-
pally to Brazil, China and India), the majority of which resulted in
increased local production and use of the vaccine. A consultation
0 of the 11 manufacturers in 2015, based on expenditure to date, future ﬁnancial
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eld in December 2010 identiﬁed the following considerations for
echnology transfer to developing countries.
Firstly, although local production does not necessarily mean
ower prices, it should be seen as a strategic investment in health.
econdly, the dynamics of technology transfer are evolving: while
he vast majority of the above-mentioned vaccine technology
ransfers were bilateral, multinational vaccine manufacturers are
ncreasingly establishing their own plants in countries with emerg-
ng economies. In order to compete with these research-driven
anufacturers, new manufacturers will need to invest in R&D, and
heir governments in an enabling environment to assure future
pportunities for technology transfer. Thirdly, increased local vac-
ine production can lead to excess supply over demand. In the
980s, this situation resulted in several vaccine manufacturers
eaving the ﬁeld and a transient shortage of some vaccines. In the
ase of seasonal inﬂuenza vaccine, the advantages in terms of health
ecurity of establishing more geographically balanced production
apacity for pandemic vaccine are considered to outweigh the risks
osed by excess capacity.
The  consultation concluded that, given limited production
apacity, technology transfer − is cost-effective and and the hub
odel where appropriate − is cost-effective and should be consid-
red for new vaccines such as conjugate pneumococcal or dengue
accines in order to ensure universal access to immunization in
eveloping countries.
.  Conclusion
In the last decade, the threat of highly pathogenic avian
nﬂuenza viruses to populations, health systems and socioeco-
omic infrastructures compelled governments across the world
o increase their preparedness for the next such emergency.
ublic health agencies, research institutions, the pharmaceuti-
al industry and major development partners are among those
hat responded rapidly to the alarm. WHO  Member States rein-
orced the importance of health security in policies and guidelines
uch as the updated International Health Regulations (2005), and
hrough innovative strategies such as the WHO  initiative to increase
nﬂuenza vaccine production capacity in developing countries.
Overall  progress of the 11 grantee vaccine manufacturers
owards their speciﬁc objectives has been impressive (results of the
ix manufacturers awarded grants in the ﬁrst round of proposals
re detailed in their respective articles published in this supple-
ent). Within a short period of time, three manufacturers have
egistered a seasonal or pandemic vaccine with their national regu-
atory authorities, even though two of these had no prior knowledge
f inﬂuenza vaccine production. Several more have reached the late
tages of clinical evaluation.
Supported  by a solid monitoring and evaluation programme
see article by Francis and Grohmann), WHO  has contributed
o increased global inﬂuenza vaccine production capacity for
[29S (2011) A2– A7 A7
more  equitable access to a life-saving vaccine during a pandemic.
Although the severity of the 2009 H1N1 pandemic was character-
ized as moderate, there is no room for complacency, as increasing
numbers of human cases of H5N1 inﬂuenza are being reported
in several countries. Support should therefore be maintained to
the current grantees and expanded to new manufacturers to allow
them to complete or initiate their technology transfer projects.
Disclaimer
This  article does not necessarily represent the decisions or the
stated policy of the World Health Organization.
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